Abstract：
UNASSIGNED: Valerian extract capsule (VEC) is an effective Chinese patent medicine used for gastrointestinal (GI) diseases.
UNASSIGNED: To investigate the detailed pharmacological activity for VEC clinical effects in GI diseases.
UNASSIGNED: Sprague-Dawley rats were divided into six groups: control, model, and drug-treated (VEC-L, VEC-M, VEC-H, and teprenone). Rats were orally administered VEC (124, 248, 496 mg/kg) and teprenone (21.43 mg/kg) for 3 consecutive days. After 1 h, the five groups (except the control group) were orally given ethanol (10 mL/kg) for 1 h or indomethacin (80 mg/kg) for 7 h. The spasmolytic activity of VEC (0.01-1 mg/mL) on ACh/BaCl2-induced New Zealand rabbit smooth muscle contraction was performed. The C57BL/6 mice carbon propelling test evaluated the effects of VEC (248-992 mg/kg) on intestinal motility in normal and neostigmine/adrenaline-induced mice.
UNASSIGNED: Compared with the model group, VEC treatment reduced the gastric lesion index and mucosal damage. Further experiments showed that the pathological ameliorative effect of VEC was accompanied by augmentation of the enzymatic antioxidant system and cytoprotective marker (COX-1, p < 0.01; PGI2 p < 0.05;), along with the alleviation of the levels of MPO (ethanol: 15.56 ± 0.82 vs. 12.15 ± 2.60, p < 0.01; indomethacin: 9.65 ± 3.06 vs. 6.36 ± 2.43, p < 0.05), MDA (ethanol: 1.66 ± 0.44 vs. 0.81 ± 0.58, p < 0.01; indomethacin: 1.71 ± 0.87 vs. 1.09 ± 0.43, p < 0.05), and inflammatory mediators. VEC decreased the high tone induced by ACh/BaCl2 and promoted intestinal transit in normal and neostigmine/adrenaline-induced mice.
UNASSIGNED: VEC showed a potential gastroprotective effect, suggesting that VEC is a promising phytomedicine for the treatment of GI diseases.
UNASSIGNED: To investigate the detailed pharmacological activity for VEC clinical effects in GI diseases.
UNASSIGNED: Sprague-Dawley rats were divided into six groups: control, model, and drug-treated (VEC-L, VEC-M, VEC-H, and teprenone). Rats were orally administered VEC (124, 248, 496 mg/kg) and teprenone (21.43 mg/kg) for 3 consecutive days. After 1 h, the five groups (except the control group) were orally given ethanol (10 mL/kg) for 1 h or indomethacin (80 mg/kg) for 7 h. The spasmolytic activity of VEC (0.01-1 mg/mL) on ACh/BaCl2-induced New Zealand rabbit smooth muscle contraction was performed. The C57BL/6 mice carbon propelling test evaluated the effects of VEC (248-992 mg/kg) on intestinal motility in normal and neostigmine/adrenaline-induced mice.
UNASSIGNED: Compared with the model group, VEC treatment reduced the gastric lesion index and mucosal damage. Further experiments showed that the pathological ameliorative effect of VEC was accompanied by augmentation of the enzymatic antioxidant system and cytoprotective marker (COX-1, p < 0.01; PGI2 p < 0.05;), along with the alleviation of the levels of MPO (ethanol: 15.56 ± 0.82 vs. 12.15 ± 2.60, p < 0.01; indomethacin: 9.65 ± 3.06 vs. 6.36 ± 2.43, p < 0.05), MDA (ethanol: 1.66 ± 0.44 vs. 0.81 ± 0.58, p < 0.01; indomethacin: 1.71 ± 0.87 vs. 1.09 ± 0.43, p < 0.05), and inflammatory mediators. VEC decreased the high tone induced by ACh/BaCl2 and promoted intestinal transit in normal and neostigmine/adrenaline-induced mice.
UNASSIGNED: VEC showed a potential gastroprotective effect, suggesting that VEC is a promising phytomedicine for the treatment of GI diseases.
摘要：
UNASSIGNED：缬草提取物胶囊（VEC）是一种有效的中成药，用于胃肠道（GI）疾病。
未经批准：研究VEC在胃肠道疾病中临床作用的详细药理活性。
UnASSIGNED：Sprague-Dawley大鼠分为六组：对照组，模型，和药物治疗(VEC-L，VEC-M,VEC-H,和teprenone）。连续3天口服给予大鼠VEC(124、248、496mg/kg)和替普瑞酮(21.43mg/kg)。1小时后，五组（对照组除外）口服乙醇（10mL/kg）1h或吲哚美辛（80mg/kg）7h。进行VEC（0.01-1mg/mL）对ACh/BaCl2诱导的新西兰兔平滑肌收缩的痉挛活性。C57BL/6小鼠碳推进试验评估了VEC（248-992mg/kg）对正常和新斯的明/肾上腺素诱导的小鼠肠运动的影响。
UNASSIGNED：与模型组相比，VEC治疗降低了胃部病变指数和粘膜损伤。进一步的实验表明，VEC的病理改善作用伴随着酶促抗氧化系统和细胞保护标记的增强（COX-1，p<0.01；PGI2p<0.05；），随着MPO水平的减轻(乙醇：15.56±0.82vs.12.15±2.60，p<0.01；吲哚美辛：9.65±3.06vs.6.36±2.43，p<0.05)，MDA（乙醇：1.66±0.44vs.0.81±0.58，p<0.01；吲哚美辛：1.71±0.87vs.1.09±0.43，p<0.05），和炎症介质。VEC降低了ACh/BaCl2诱导的高音调，并促进了正常和新斯的明/肾上腺素诱导的小鼠的肠道运输。
未经授权：VEC显示出潜在的胃保护作用，表明VEC是治疗胃肠道疾病的有前途的植物药。
未经批准：研究VEC在胃肠道疾病中临床作用的详细药理活性。
UnASSIGNED：Sprague-Dawley大鼠分为六组：对照组，模型，和药物治疗(VEC-L，VEC-M,VEC-H,和teprenone）。连续3天口服给予大鼠VEC(124、248、496mg/kg)和替普瑞酮(21.43mg/kg)。1小时后，五组（对照组除外）口服乙醇（10mL/kg）1h或吲哚美辛（80mg/kg）7h。进行VEC（0.01-1mg/mL）对ACh/BaCl2诱导的新西兰兔平滑肌收缩的痉挛活性。C57BL/6小鼠碳推进试验评估了VEC（248-992mg/kg）对正常和新斯的明/肾上腺素诱导的小鼠肠运动的影响。
UNASSIGNED：与模型组相比，VEC治疗降低了胃部病变指数和粘膜损伤。进一步的实验表明，VEC的病理改善作用伴随着酶促抗氧化系统和细胞保护标记的增强（COX-1，p<0.01；PGI2p<0.05；），随着MPO水平的减轻(乙醇：15.56±0.82vs.12.15±2.60，p<0.01；吲哚美辛：9.65±3.06vs.6.36±2.43，p<0.05)，MDA（乙醇：1.66±0.44vs.0.81±0.58，p<0.01；吲哚美辛：1.71±0.87vs.1.09±0.43，p<0.05），和炎症介质。VEC降低了ACh/BaCl2诱导的高音调，并促进了正常和新斯的明/肾上腺素诱导的小鼠的肠道运输。
未经授权：VEC显示出潜在的胃保护作用，表明VEC是治疗胃肠道疾病的有前途的植物药。
